Drug intelligence / Profile preview

PM 908

Development stage: Preclinical
Lead developer: Phytomyco Research
Modality: Small Molecules
Administration: Oral

Overview

PM 908 is a preclinical-stage natural product and nutraceutical candidate being developed by Phytomyco Research for the treatment of diabetes. Positioned as a backup candidate within the company's nutraceutical pipeline, it is derived from plant sources and intended for anti-diabetic applications. As a natural product-based therapeutic, it aims to provide a metabolic management option, though its specific molecular targets and mechanism of action have not been publicly disclosed.

Other names: PM 908PM908PM-908

Beyond the preview

Go deeper on PM 908.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM 908.

Explore the full profile